Similarly, treatment with pan-kinase inhibitors or selective RTKi, namely HS10241, with the PARPi fluzoparib synergistically suppressed tumor growth in multiple cancer types both in vitro and in vivo [32], which is consistent with our findings indicating that PDAC cancer stem cells were more sensitive to the FGFR1 inhibitor PD173074 in the absence of PARP1, in vivo (Figure 6). This evidence concerns the gene PARP1 and cancer.